Noureddin Mazen, Rinella Mary E
Division of Gastrointestinal and Liver Diseases, USC Keck School of Medicine, 2011 Zonal Avenue, HMR 101, Los Angeles, CA 90033, USA.
Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Arkes Pavillion 14-005, Chicago, IL 60611, USA.
Clin Liver Dis. 2015 May;19(2):361-79. doi: 10.1016/j.cld.2015.01.012. Epub 2015 Mar 12.
Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC). NAFLD is the commonest cause of chronic liver disease. HCC can develop in NAFLD patients even without cirrhosis, suggesting an association between the metabolic process and HCC and raising a concern that many cancers could be missed given high NAFLD prevalence and screening limitations. The increasing prevalence of these conditions and lack of effective treatments necessitate a better understanding of their connection. This article defines the known interrelationships and common pathways between NAFLD, diabetes, obesity and HCC and possible chemoprevention strategies.
糖尿病和肥胖与非酒精性脂肪性肝病(NAFLD)以及肝细胞癌(HCC)发病率增加相关。NAFLD是慢性肝病最常见的病因。即使没有肝硬化,NAFLD患者也可能发生HCC,这表明代谢过程与HCC之间存在关联,并引发了一种担忧,即鉴于NAFLD的高患病率和筛查局限性,许多癌症可能会被漏诊。这些疾病的患病率不断上升且缺乏有效的治疗方法,因此有必要更好地了解它们之间的联系。本文阐述了NAFLD、糖尿病、肥胖和HCC之间已知的相互关系和共同途径,以及可能的化学预防策略。